RxSight raises FY24 revenue view to $139M-$140M from $132M-$137

Consensus $135.07M. The company said, “The company increased its 2024 full-year revenue and operating expense guidance as follows: Revenue in the range of $139.0 million to $140.0 million, representing implied growth of 56% to 57% compared to 2023, up from prior guidance of $132.0 million to $137.0 million; Operating expenses in the range of $135.0 million to $136.0 million, representing an implied increase of 30% to 31% compared to 2023, up from prior guidance of $126.0 million to $130.0 million and including higher non-cash stock-based compensation expense guidance in the range of $29.0 million to $30.0 million, up from prior guidance of $22.0 million to $25 million. Additionally, gross margin full-year 2024 guidance remained unchanged in the range of 68% to 70%.”